2020
Gomori Methenamine Silver Stain on Bronchoalveolar Lavage Fluid Is Poorly Sensitive for Diagnosis of Pneumocystis jiroveci Pneumonia in HIV-Negative Immunocompromised Patients and May Lead to Missed or Delayed Diagnoses
Azar MM, Slotkin R, Abi-Raad R, Liu Y, Grant MH, Malinis MF. Gomori Methenamine Silver Stain on Bronchoalveolar Lavage Fluid Is Poorly Sensitive for Diagnosis of Pneumocystis jiroveci Pneumonia in HIV-Negative Immunocompromised Patients and May Lead to Missed or Delayed Diagnoses. Archives Of Pathology & Laboratory Medicine 2020, 144: 1003-1010. PMID: 31904277, DOI: 10.5858/arpa.2019-0394-oa.Peer-Reviewed Original ResearchHIV-negative immunocompromised patientsBronchoalveolar lavage fluidDiagnosis of PJPHIV-positive patientsImmunocompromised patientsLavage fluidGomori methenamine silver stainingPneumocystis jiroveci pneumoniaHIV-positive casesHuman immunodeficiency virusGomori methenamine silver stainMethenamine silver stainingMethenamine silver stainJiroveci pneumoniaBAL fluidHistorical gold standardRetrospective reviewImmunodeficiency virusPatientsLow burdenDiagnosisGMS stainGold standardPJPPneumonia
2016
Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation
Azar MM, Malinis MF, Moss J, Formica RN, Villanueva MS. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. International Journal Of STD & AIDS 2016, 28: 447-458. PMID: 27193421, DOI: 10.1177/0956462416651528.Peer-Reviewed Original ResearchConceptsInhibitor-based regimensRenal transplantationHIV/AIDSAntiretroviral regimenAntiretroviral therapyGraft survivalHIV-positive renal transplant recipientsEnd-stage renal diseaseHIV-positive patientsRenal transplant recipientsChronic kidney diseaseThree-year survivalInhibitor-based therapyNon-nucleoside reverseDrug-drug interactionsTransferase inhibitorsImmunosuppressive medicationsKidney transplantationTransplant recipientsAllograft rejectionGraft failureRenal diseaseCalcineurin inhibitorsClinical outcomesImmunosuppressive drugs